Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Cara Therapeutics, Inc.    CARA

CARA THERAPEUTICS, INC.

(CARA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news

CARA THERAPEUTICS, INC. : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K)

11/09/2020 | 04:12pm EST

Item 2.02. Results of Operations and Financial Condition.

On November 9, 2020, Cara Therapeutics, Inc. (the "Company") issued a press release announcing its financial results for the third quarter ended September 30, 2020. A copy of the press release is being furnished to the Securities and Exchange Commission as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference to this Item 2.02.

The information furnished pursuant to this Item 2.02, including Exhibit 99.1, shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference into any of the Company's filings with the Securities and Exchange Commission under the Exchange Act or the Securities Act of 1933, as amended, whether made before or after the date hereof, regardless of any general incorporation language in such a filing.

Item 9.01. Financial Statements and Exhibits.




(d)         Exhibits

Exhibit No.   Description

99.1 Press Release dated November 9, 2020 104

           Cover page interactive data file (formatted as Inline XBRL)

© Edgar Online, source Glimpses

All news about CARA THERAPEUTICS, INC.
01/12CARA THERAPEUTICS : Initiates Phase 2 Trial of Oral KORSUVA for the Treatment of..
AQ
01/11CARA THERAPEUTICS : Begins Phase II Study of Difelikefalin for Treatment of Prur..
MT
01/11Cara Initiates Phase 2 Trial of Oral KORSUVA™ for the Treatment of Prur..
GL
01/06CARA THERAPEUTICS : to Present at the 39th Annual J.P. Morgan Healthcare Confere..
AQ
2020CARA THERAPEUTICS : Submits New Drug Application to U.S. Food and Drug Administr..
AQ
2020CARA THERAPEUTICS, INC. : Regulation FD Disclosure, Financial Statements and Exh..
AQ
2020CARA THERAPEUTICS : Submits New Drug Application for Korsuva Injection
MT
2020Cara Therapeutics Submits New Drug Application to U.S. Food and Drug Administ..
GL
2020SWK : ' Subsidiary, Enteris BioPharma, Receives $2.5Million Milestone Payment fr..
MT
2020CARA THERAPEUTICS : SWK Holdings' Subsidiary, Enteris BioPharma, Receives Second..
PR
More news
Financials (USD)
Sales 2020 65,7 M - -
Net income 2020 -53,3 M - -
Net Debt 2020 - - -
P/E ratio 2020 -12,7x
Yield 2020 -
Capitalization 925 M 925 M -
Capi. / Sales 2020 14,1x
Capi. / Sales 2021 32,8x
Nbr of Employees 76
Free-Float 83,9%
Chart CARA THERAPEUTICS, INC.
Duration : Period :
Cara Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CARA THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 8
Average target price 33,13 $
Last Close Price 18,56 $
Spread / Highest target 116%
Spread / Average Target 78,5%
Spread / Lowest Target -3,02%
EPS Revisions
Managers and Directors
NameTitle
Derek T. Chalmers President, Chief Executive Officer & Director
Thomas Reilly Chief Financial & Accounting Officer
Frèdèrique Menzaghi Chief Scientific Officer, Senior VP-R&D
Joana Goncalves Chief Medical Officer
Martin A. Vogelbaum Lead Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
CARA THERAPEUTICS, INC.22.67%925
MODERNA, INC.24.10%51 304
LONZA GROUP AG3.27%49 041
CELLTRION, INC.-8.36%40 715
IQVIA HOLDINGS INC.4.81%36 004
SEAGEN INC.6.06%33 601